3M will spin off its health care business into a new public company

A 3M logo is seen atop a Versaflo TR-300+ powered air purifying respirator hood as Nurse Evan Brost puts on personal protective equipment (PPE) before entering a patient room in a wing housing coronavirus disease (COVID-19) patients at UW Health University Hospital in Madison, Wisconsin, U.S. November 18, 2020.

Daniel Acker | Reuters

3M announced Tuesday that it will spin off its health care business into a separate publicly traded company.

The new business will focus on wound and oral care, healthcare IT and biopharma filtration, the material science company said in a release.

The announcement comes as 3M spins off another company focusing on food safety, a process which is scheduled to be completed by September.

This is breaking news. Please check back for updates.

Source

Health

RFK Jr. removes all members of CDC panel advising U.S. on vaccines

June 9, 2025

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before the Senate Committee on Appropriations hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 20, 2025. Ken Cedeno | Reuters Health and Human Services Secretary Robert F. Kennedy Jr. on Monday said he […]

Health

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

June 9, 2025

The Food and Drug Administration on Monday approved Merck’s shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead […]

Health

JPMorgan’s top biotech and pharma picks for the second half

June 6, 2025

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]